Using KinetiSol Technology to Improve an Abandoned Prostate Cancer Medication (Galeterone)

In 2019, there were approximately 175,000 new cases of prostate cancer, contributing to 10% of male cancer-related fatalities. Galeterone, a novel prostate cancer candidate treatment, was discontinued after a Phase III clinical trial due to lack of efficacy. This Case Study explores how KinetiSol outperforms Spray Dried ASD and helped bring Galeterone to market.